Pfizer CEO Denies Licensing Paxlovid to Chinese Generics Firms
Pfizer Inc. (NYSE: PFE) CEO Albert Bourla, speaking on the sidelines of the JPMorgan Healthcare...
NYSE: PFE
Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute
The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...
Shyndec’s Generic Cytosar-U Gains Marketing Approval in China
China-based Shanghai Shyndec Pharmaceutical Co., Ltd (SHA: 600420) has announced that its generic version of...
Pfizer Exercises Option for Sisunatovir Rights with LianBio
US major Pfizer Inc. (NYSE: PFE) has agreed with China-based LianBio (OTCMKTS: LIANY) to exercise...
Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based...
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...
Pfizer’s Zavicefta Approved in China for Pediatric Complex Intra-Abdominal Infections
US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced that it has received market approval from...
Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC
US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2...
Pfizer’s Besponsa First Prescribed in China for Leukemia Treatment
US major Pfizer (NYSE: PFE) has announced the first prescriptions for its leukemia therapy Besponsa...
Pfizer’s Lorbrena Receives First Prescription in China for NSCLC Treatment
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the first prescription of its third-generation...
Pfizer’s Ritlecitinib Earns CDE Breakthrough Designation for Ulcerative Colitis
The Center for Drug Evaluation (CDE) website indicates that Pfizer’s (NYSE: PFE) category 1 drug...